Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly & Co.

2Q Revenues: $4.6 billion (+14%)

2Q Earnings: $664 million (-19%)

YTD Revenues: $8.9 billion (+13%)

YTD Earnings: $1.2 billion (-29%)

Comments: Net income was impaired by the purchases of Hypnion and Ivy Animal Health. Cymbalta was the top gainer, with 2Q sales rising 67% to $520 million. Zyprexa sales grew 9% to $1.2 billion while #3 seller Gemzar posted sales of $396 million (+15%). R&D expenses rose 10% to $854 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters